UPDATE: Incyte (INCY) Tops Q3 EPS by 12c, Beats on Revenues; Boosts FY17 Jakafi Net Product Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Incyte (INCY), AstraZeneca (AZN) Expand Clinical Trial Collaboration in Early Lung Cancer
October 31, 2017 6:20 AM EDTIncyte Corporation (Nasdaq: INCY) and MedImmune, AstraZenecas (NYSE: AZN) global biologics research and development arm, today announced the expansion of their clinical collaboration. As part of the agreement, the companies will evaluate the efficacy and safety of epacadostat, Incytes investigational selective IDO1 enzyme inhibitor, in combination with AstraZenecas Imfinzi® (durvalumab), a human monoclonal antibody directed against PD-L1, compared to Imfinzi alone.
The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial in patients with locally-advanced (Stage III), unresectable non-small cell lung... More
Incyte Corporation (INCY) Appoints Jacqualyn A. Fouse, Ph.D to Board
October 30, 2017 4:47 PM EDTIncyte Corporation (NASDAQ: INCY) today announced the appointment of Jacqualyn Jackie A. Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017.
We are pleased to welcome Jackie to Incyte. Her impressive background will further strengthen and add to the experience of our Board and leadership team, stated Hervé Hoppenot, Incytes Chairman and Chief Executive Officer. We look forward to... More
